Trial Profile
A Randomized, Placebo-controlled, Phase II Pilot Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Aug 2014
Price :
$35
*
At a glance
- Drugs Angiotensin II (Primary)
- Indications Hypotension
- Focus Therapeutic Use
- Sponsors La Jolla Pharmaceutical Company
- 06 Aug 2014 New trial record
- 08 Jul 2014 Results published in the La Jolla Pharmaceutical Company Media Release.